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Introduction
In developed countries, ageing is the most important
risk factor for age and death after age 28. Age also
determines the onset and development of the most
prominent vascular and renal diseases, atherosclerosis
and glomerulosclerosis. Increased vascular and renal
oxidative stress, and, as a consequence, abnormal
activity of endothelium-derived molecules, such as
nitric oxide (NO), angiotensin II and endothelin,
are now recognized as important mechanisms control-
ling these disease processes. In this article, I will discuss
current evidence for the involvement of endothelial
factors in the genesis of vascular dysfunction and
cardiorenal disease seen with ageing and present
therapeutic approaches to actively interfere with
these disease processes.
‘Aging changes can be attributed to development,
genetic defecects, the environment, disease, and the
inborn aging process
The latter is the major risk factor for disease and
death after age 28 in the developed countries’.
Denham Harman [1].
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Ageing and development of cardiorenal diseases
The majority of deaths worldwide in the year 2020 will
be due to cardiovascular causes, and a substantial
proportion of this number will be due to the increase in
the aged population expected in the next two decades
[2,3] Moreover, ageing will continue to be the most
important determinant of disease in Western societies
[1]. Ageing not only promotes the development of
vascular disease and glomerulosclerosis [4], but is also
associated with signiﬁcant metabolic changes, resulting
in age-dependent increases of the body mass index,
development of insulin resistance and/or diabetes, as
well as changes in lipid metabolism [5–9]. The
incidence of hypertension increases in the elderly and
may be related to enhanced sodium sensitivity and
activation of the sympathetic nervous system (which
are also charactaristic features of chronic renal failure
[10]), as well as abnormal responses to certain drugs
such as non-steroidal anti-inﬂammatory drugs
(NSAIDs) [11]. Since all the changes described above
may contribute to atherogenesis, one could argue that
the increase in renal and vascular disease seen with
ageing could be simply explained by these distur-
bances. However, the pathogenesis of age-dependent
diseases appears to be more complex since it also
involves local cellular changes in the kidney, the
vasculature and circulating blood cells (reviewed in
[12]).
Cell injury precedes onset and determines
progression of disease
Endothelial cells form the inner lining of arterial blood
vessels and amount to 1.5 kg, covering an area of
approximately four tennis courts [13]. Under healthy
conditions, endothelial cells constantly produce a
number of vasoactive and trophic substances that
control inﬂammation, vascular growth, vasomotion,
platelet function, and plasmatic coagulation. Among
others, these substances include prostacyclin, NO,
superoxide anion (O2
), angiotensin II, as well as
endothelin-1 (reviewed in [13,14]). If disease—or phy-
siological processes such as ageing or menopause—
sets in, endothelial cell function deteriorates, and the
ﬁnely tuned release of growth inhibitors and mitogens
becomes dysbalanced (Figure 1).
In the vasculature, early lesions of the atherosclero-
tic plaque (fatty streaks) consisting of endothelial
deposits of lipid-laden macrophages [15] can be
detected in the fetal aorta, and their progression is
aggravated by maternal hypercholesterolaemia [16].
This suggests that lipids play an essential role for
disease onset and progression of atherosclerosis
already early in life. Vascular endothelial cell injury
is a key event in atherogenesis [15], indicating that
under normal conditions intact endothelial cells
protect from atherosclerosis. Similarly, in the kidney,
damage of glomerular endothelial cells has been
reported to contribute substantially to sclerosis of the
glomerulus [12]. Consequently, endothelial factors
such as endothelin-1 have been identiﬁed to play a
direct role in the genesis of experimental glomerulo-
sclerosis and atherosclerosis (reviewed in [14]), and
analogies between ‘accelerated ageing’ and uraemia
have been proposed [17]. Thus, it would not
be surprising if changes in production and/or activity
of these mediators with ageing would either promote
or delay the disease process. Some of the ﬁrst direct
evidence for this hypothesis will be discussed below.
Importance of the L-arginine/nitric oxide pathway
NO, a short-lived gaseous molecule, is the most
important endogenous vasodilator, which also shares
strong anti-aggregatory and anti-inﬂammatory proper-
ties [18]. NO reacts with O2
 at a diffusion-limited rate
of 6.7 109/s, thereby reducing the bioactivity of NO
and resulting in formation of the cytotoxic peroxy-
nitrite [19]. In rats, a species normally resistant to
atherosclerosis but not to glomerulosclerosis, ageing is
associated with a marked decrease of basal [20] as
well as stimulated endothelial NO bioactivity in the
systemic arterial circulation [20,21]. Impaired function
of endothelium-dependent pathways has also been
observed in rat coronary arterioles [24], vessels which
in humans do not develop atherosclerosis even if
epicardial arteries are affected. An attenuation of
endothelium-dependent vasodilatation with ageing has
been observed in the human brachial artery [22].
The age-associated reduction of NO bioactivity
is associated with an increase in expression of the
‘inﬂammatory’ isoform of NO synthase, NOS2 [23,24],
increased NADPH oxidase activity and formation of
O2
 [24,25]. As a consequence, vascular peroxinitrite
formation increases, causing nitrosylation and func-
tional alteration of vascular proteins [19,24]. Indirect
evidence suggests that alterations of the L-arginine/NO
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Fig. 1. Proposed mechanisms of the vascular and renal ageing
process. A continous increase in cellular oxidative stress with ageing
results in a shift promoting activity and production of vasoactive
mediators. Enhanced formation of growth-promoting factors such
as superoxide anion, angiotensin II and endothelin-1 counteracts
the loss of anti-inﬂammatory and growth inhibitory mediators such
as nitric oxide and prostacyclin with increasing age.
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pathway also occur with ageing. These observations
include reductions of circulating NO metabolites [26]
and changes in basal NO release [20,27], as well as
reduced renal NO metabolite excretion [27]. While
vascular NOS2 expression increases with ageing
[23,24], NOS3 isoenzyme expression appears to be
regulated depending on gender [20,23]. We have shown
previously that in aged Wistar rats, aortic NOS3 gene
expression decreases in females [20] while an increase
occurs in males [23]. This ﬁnding has been conﬁrmed
recently by Pollock’s group, who found a similar
regulation pattern in aged rat mesenteric arteries [28].
With intermediate ageing, tissue levels of the stable NO
metabolites, nitrate/nitrate, decrease in the kidney [29].
However, with advanced ageing, changes occur in an
anatomically distinct pattern, showing decreased levels
of NO metabolites selectively in the renal cortex but
not in the medulla [30]. This selective regulation of
NO bioactivity may be related to distinct local changes
of factors regulating renal NO release, such as local
increases in endothelin-3 [30,31].
Other endothelial factors, such as vascular endo-
thelial growth factor (VEGF), also appear to be
involved in age-dependent changes and are regulated
in an NO-dependent fashion. There is experimental
evidence to suggest that the ability for tissue repair
through sprouting of new vessels (angiogenesis), which
requires the presence of VEGF, is impaired in aged
mice [32,33]. Plasmid-mediated gene transfer of DNA
encoding human VEGF165 can increase hindlimb
angiogenesis in aged animals after 40 days comparably
with the degree of vascularization seen in untreated
young animals. Whether the expression of VEGF and
its therapeutic effects on angiogenesis can also be
achieved thereafter remains uncertain. Also, given the
safety concerns that arose from human VEGF gene
therapy trials, it is unlikely that gene therapy
represents an option to interfere successfully with
vascular ageing in humans.
Age-associated changes due to endothelial
factors: truly irreversible?
Over the past centuries, scientists have developed more
than 300 theories to explain the ageing phenomenon,
many of which are based on the notion that age-
dependent changes accumulate with time [34]. The ‘free
radical theory of ageing’ was put forward by Denham
Harman already half a century ago (reviewed in
[34,35]) and is based on the chemical nature and
ubiquitous presence of free radicals. Indeed, several
lines of evidence now indicate that cellular oxidative
stress caused by reactive oxygen species (ROS) is an
important factor contributing to ageing-associated
organ injury. In addition to ROS-induced DNA
damage in the nucleus as well as in mitochondria,
ageing of endothelial cells is associated with an
‘inﬂammatory’ phenotype as well as alterations of
cell organelles, signs of cell senescence, abnormal
activity of cellular mediators and/or enzymes and
vascular reactivity of vascular smooth muscle cells
[23,29,36–39]. At the level of the endothelial cell,
oxidative stress causes cellular damage by oxidative
modiﬁcation of expression and function of proteins
[37–39]. Therefore, it would be desirable that any
treatment aiming at interfering with or even restoring
abnormal age-dependent function or structure should,
at some point, inhibit the production and/or activity of
ROS or enzymes involved in ROS production. There is
evidence suggesting that in certain forms of disease,
ROS inhibition favourably affects outcome. Indeed,
blockade of endothelin receptors in experimental
diabetes recently has been shown to inhibit expression
of the NAPDH oxidase subunit p22phox, an important
source of vascular ROS [40,41], and similar data have
been obtained with angiotensin AT1 receptor blockers
(ARBs) [42]. Thus, is it not surprising that angiotensin-
converting enzyme inhibitors (ACEIs) and ARBs
as well as endothelin receptor blockers are effective
in preventing experimental age-related functional
changes of arterial endothelial cells [43–45].
Experimental studies indicate that endothelium-
dependent relaxant responses to acetylcholine are
markedly reduced in the aged rat aorta, whereas the
response is maintained in certain vessels such as the
femoral [20] or the mesenteric artery [28]. A similar
heterogeneity has been described with regard to expres-
sion of cyclooxygenase isoenzymes between ageing
rat aorta and superior mesenteric artery [46]. These
experimental data suggest that not only mediator
activity but also transcriptional regulation of enzymes
regionally differ within the ageing vasculature.
If applicable for the human situation, this could at
least in part explain the heterogeneity of suscepti-
bility to atherosclerosis. Indeed, certain arteries such
as the internal mammary artery and the radial artery
rarely develop atherosclerosis even up to high age.
Vascular activity of the antioxidant enzyme superoxide
dismutase in rats is not altered by ageing [20].
In addition to the impaired NO bioactivity, which
wouldpromotevasoconstriction, there are also increases
in vascular reactivity to vasoconstricting substances
such as angiotensin II, endothelin-1 [29], vasoconstric-
tor prostanoids like prostaglandin H2/thromboxane
A2, and enzyme expression of prostaglandin H synthase
[46,47]. It has been shown by Remuzzi and co-workers
that inhibiting the activity of angiotensin II slows the
development of age-dependent glomerulosclerosis in
conjuction with blood pressure lowering and a reduc-
tion of tubulointerstitial injury [49]. One of the most
potent endothelial factors, endothelin-1, not only
directly impairs vasomotion [48], but also controls
pathological processes related to ageing. Based on our
previous observation that ageing increases renal
endothelin expression in the absence of hypertension
[23,29], we recently have addressed the question of
whether this activation might contribute to the patho-
genesis of spontaneous glomerulosclerosis in the ageing
kidney. Unexpectedly, we found that short-term inhibi-
tion of endothelin ETA receptors using darusentan
reversed established glomerulosclerosis and proteinuria
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in aged rodents, effects that were associated with partial
restoration of podocyte structure [50]. Interestingly,
restoration of glomeruli was associated with decreased
expression of p21WAF/CIP1 and matrix metalloprotei-
nase-9, and independent of tubulo-interstitial injury,
blood pressure, creatinine clearance or renal blood ﬂow
[50]. This indicates that ageing adversely affects the
structure of the renal glomerulus in a locally conﬁned
and reversible manner, involving ETA receptor-
mediated mechanisms that are also involved in the
regulation of age-dependent changes in electrolyte
excretion [51].
Therapeutic approaches
There are several options to improve vascular function
in the ageing vasculature. In additition to the experi-
mental data using gene transfer, there are complemen-
tary approaches for ‘therapeutic’ angiogenesis and
maintaining vascular function such as exercise training
and certain cardiovasculas drugs. In healthy animals,
angiogenesis was increased in trained rodents as com-
pared with sedentary animals, and the beneﬁcial
effect was abrogated by an anti-VEGF antibody [52].
A recent study in a transgenic mouse model of ageing
also suggests that age-dependent reduction of angio-
genesis can be effectively prevented by use of statin
therapy [53]. Physical training in humans also helps to
counteract the impairment of endothelium-mediated
vasodilatory capacity normally seen with ageing
[22,54–56], also suggested by a study comparing
untrained with trained elderly men above 70 years of
age [57]. Interestingly, exercise in the lower extremities
may affect endothelial vasomotion in remote organs
such as the arm [58], suggesting that physical exercise
has systemic and possibly sustained beneﬁcal effects.
As outlined in Figure 2, several modalities are
available to interfere with age-related changes in
endothelial cell function. Preventive measures, which
are often already applicable for juveniles, include
cessation of smoking, reduction of increased body
weight, and avoiding unbalanced diets rich in fat and
sugars and low in ﬁbres. Interestingly, nutritional
additives such as vitamins appear to be largely
ineffective in interfering with age-dependent functional
changes. As ageing is frequently associated with a
reduction of physical activity and ﬁtness [59], it is even
more important to emphasize the ‘therapeutic’ role of
regular physical activity, which also helps to reduce
the incidence and severity of related co-morbidities
such as diabetes, high blood pressure, dyslipidaemia
and obesity [60]. Finally, cardiovascular health aware-
ness must be increased not only in the elderly but
also in parents, including regular check-ups with their
primary care physician, awareness of risk factors/
blood cholesterol levels, and blood pressure measure-
ments. If these changes in lifestyle have been imple-
mented and are still insufﬁcient, medical therapy
aiming at improving vascular and renal homeostasis,
and reversibly restoring organ dysfunction, such as
cardiac hypertrophy or proteinuria, using statins,
inhibitors of the renin–angiotensin–aldosterone
system (RAAS), or possibly the endothelin system
can be initiated. It can be anticipated that maintain-
ing or even improving cardiorenal health with age
is not only likely to result in improved general health
but can also be expected to have have a positive impact
on cardiovascular and renal morbidity and mortality
[61–63].
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Why patients with progressing kidney disease are referred late
to the nephrologist: on causes and proposals for improvement
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The adverse effects arising from late referral (LR) have
been reported by nephrologists over the past 20 years
from several countries [1–10]: not only does LR
delay the introduction of measures to attenuate the
progressive loss of kidney function and prevent
uraemic complications [11], but LR has also numerous
short and long-term deleterious effects on clinical
outcome [1–8]. The only study that did not conﬁrm the
long-term harmful effects of LR is the study of
Roubicek et al. [12]. It appears, however, that their
deﬁnition of LR was longer (4 months before dialysis),
patients were younger, with less co-morbidities and
relatively long hospitalization times in both patient
groups, and a shorter mean survival time of the early
referral group than in most other patient series.
While a recent review analyzed the relationships
between LR, mortality and morbidity, and the
potential positive effects of early referral [10], the
present editorial comment identiﬁes and analyzes the
different causes responsible for LR and suggests some
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